We rank companies based on fund manager, research analyst and news sentiment
GLMD stock icon

Galmed Pharmaceuticals


About: Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.

Employees: 8

Funds holding %
of 6,474 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

3.79% less ownership

Funds ownership: 18.14% [Q3] → 14.35% (-3.79%) [Q4]

19% less funds holding

Funds holding: 16 [Q3] → 13 (-3) [Q4]

42% less capital invested

Capital invested by funds: $429K [Q3] → $249K (-$180K) [Q4]

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Research analyst outlook

We haven’t received any recent analyst ratings for GLMD.

Financial journalist opinion